IBI-362
Type 2 Diabetes/Obesity
Phase 3Active
Key Facts
About Innovent Biologics
Innovent Biologics' mission is to develop and commercialize high-quality, innovative medicines that are affordable and accessible to patients worldwide. Its key achievements include a successful 2018 Hong Kong IPO, the commercialization of multiple blockbuster products like Tyvyt® (sintilimab), and the establishment of a deep, diversified pipeline through internal R&D and strategic partnerships. The company's strategy hinges on full integration, global expansion, and leveraging its robust technology platforms to deliver a sustainable portfolio of novel biologics.
View full company profileTherapeutic Areas
Other Type 2 Diabetes/Obesity Drugs
| Drug | Company | Phase |
|---|---|---|
| Biosimilars (e.g., Semaglutide) | Phenotypeca | Commercial |
| HS-10511 | Hansoh Pharma | Phase I |